Search

Search Results

• 

  PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven^1|9, E. Van Gansewinkel^5|10, J. De Bruijne², F. Eskens³, D. De Groot⁴, K. Hermans⁵, N. Mohammad⁶, F. Van Vilsteren⁷, C. Verslype⁸, W. Moris⁹, M. Roest¹⁰, B. De Laat¹⁰ , J. De Vos-Geelen⁵, M. Kramer^1|9 | ¹Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; ²Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; ³Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; ⁴Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; ⁵Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; ⁶Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; ⁷Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; ⁸Digestive Oncology, University Hospitals Leuven, Belgium; ⁹Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; ¹⁰Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.554

  103

  PDF: 19